Kardigan, Inc.
Clinical trials sponsored by Kardigan, Inc., explained in plain language.
Kardigan, Inc.
KARD
NASDAQ
A biopharmaceutical company developing therapies for cardiovascular diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot aims to keep blood pressure in check after hospital discharge Results expected Dec 2026 (estimated)
- New pill aims to strengthen hearts in genetic cardiomyopathy Results expected Sep 2027 (estimated) 🚀 Make-or-break